Mechanistically, miR-33b directly targets TAK1, thereby decreasing the expression of FASN and CPT1A in ovarian cancer cells, which reduces OCM-promoted fatty acid synthesis and ATP production. The gene discussed is OCM; the disease is ovarian carcinoma.